JSC Olpha, the leading pharmaceutical manufacturer in the Baltics, continues to strengthen its research and innovation activities by establishing a new group company, Olpha Labs Ltd. The company’s objective will be to develop and expand the export of pharmaceutical development and research services in international markets.
The pharmaceutical industry is one of Latvia’s highest value-added sectors. Until now, our focus has been on manufacturing our own medicines, but the export of pharmaceutical development and research services is also an area with significant growth potential. By establishing Olpha Labs, we are taking the next step toward developing internationally competitive research and drug development services in Latvia.
Dr. Juris Hmeļņickis, Chairman of the Management Board of JSC Olpha and Olpha Labs Ltd
The new company will continue the work of the Research and Development Center of JSC Olpha, focusing on the development of new products, the advancement of scientific expertise, and collaboration with international partners.
Olpha Labs Ltd. will enable the consolidation of research competencies within a single structure, facilitate more efficient management of innovation projects, and strengthen cooperation with foreign partners.
At the same time, the company expects this model to enhance Latvia’s position in the pharmaceutical and life sciences sectors while creating additional demand for highly qualified specialists.
“We are seeing growing international demand for high-quality research and development services that we are capable of providing. The establishment of Olpha Labs will allow us to further strengthen our scientific expertise, accelerate the development of new products, and participate more actively in international cooperation projects. In this way, we continue to strengthen Latvia as a modern, knowledge-based economy whose competitiveness is built on innovation, high added value, and international collaboration,” said Eriks Ivanovskis, former Director of the Research and Development Center of JSC Olpha, who will continue his work as part of the management team of Olpha Labs Ltd.
The Chairman of the Management Board of Olpha Labs Ltd. will be Dr. Juris Hmelnickis, Chairman of the Management Board of JSC Olpha. The new company will employ 50 specialists.
Following the change in its majority shareholders, JSC Olpha has been actively expanding its portfolio of generic medicines and strengthening its presence in Western markets. To date, eight new medicines from the company’s new product portfolio have been launched in the European Union, and by the end of the year the number is expected to exceed 20 products across therapeutic areas including cardiology, pulmonology, neurology and psychiatry, endocrinology, oncology, and others.
The new products are currently available in the Baltic States, the Czech Republic, Italy, Slovakia, Poland, and France.
17.06.2026.
